Northwest Biotherapeutics receives $15M in financing
Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, has secured $15 million in financing to accelerate its brain cancer program. Read More
Bone Therapeutics, Link Health enter agreement for rights of ALLOB
Bone Therapeutics and Link Health Pharma have signed a nonbinding agreement for the global rights regarding the development, manufacturing, and commercialization of ALLOB, Bone Therapeutics' off-the-shelf, human, allogeneic bone cell therapy derived from bone marrow mesenchymal stromal cells. The two companies plan to sign a binding license agreement by the end of 2021. Read More
Turnstone, Moffitt Biologics to advance TIL immunotherapies for solid tumors
Turnstone Biologics has entered into a strategic multiyear research collaboration with the Moffitt Cancer Center for the preclinical development of investigational tumor-infiltrating lymphocyte (TIL) therapies. The partnership will focus on new clinical candidates using Turnstone's next-generation TIL approach in treating multiple solid tumors. Read More
CRISPR Therapeutics granted FDA RMAT for CTX110 for CD19+ B-cell cancers
CRISPR Therapeutics received the U.S. Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation for CTX110, an allogeneic CAR T-cell therapy, for the treatment of relapsed or refractory CD19+ B-cell malignancies. Read More
Researchers create artificial nanopores capable of detecting DNA
Scientists have designed bottom-up peptides that can form artificial nanopores to identify and enable single molecule-sorting of genetic material in a lipid membrane, according to new research published in Nature Nanotechnology on November 22. Read More
Neurophth raises over $60M to advance gene therapies
Neurophth Therapeutics has raised over $60 million in series C financing to advance gene therapies for ophthalmic diseases. Read More
Asgard Therapeutics raises seed funding for novel in vivo cancer immunotherapy
Asgard Therapeutics, a private biotech startup based in Lund, Sweden, has raised 6 million euros (about $6.8 million) in seed financing, co-led by Novo Holdings, a global life science investor based in Hellerup, Denmark. Read More
Cytovia, Cellectis expand partnership to boost collaboration in China
Cytovia Therapeutics and Cellectis have expanded their partnership on transcription activatorlike effector nuclease gene-edited iNK (NK cells derived from induced pluripotent stem cells) to allow for a broader collaboration in China. Read More
Regeneron extends research agreement with Decibel Therapeutics
Regeneron has extended its research agreement with Decibel Therapeutics for the development of gene therapies for hearing loss. Read More
BMS awards 'golden tickets' to promising biotech startups
Bristol-Myers Squibb (BMS) has given its 2021 Golden Ticket awards to five startup biotechnology companies. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter